Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced exciting news today: the first patient has been dosed in a clinical trial sponsored by Sanofi, evaluating the potential of SAR’514 / IPH6401 to treat relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA). This marks an important milestone in Innate’s ongoing efforts to develop innovative treatments for these devastating diseases.
SAR’514 is a revolutionary anti-BCMA NKp46xCD16 NK cell engager, developed with two of the most advanced immune-focused platforms, Sanofi’s CROSSODILE® multi-functional platform and Innate’s ANKET® (Antibody-based NK cell Engager Therapeutics).
SAR’514 is designed to induce dual targeting of NK activating receptors, NKp46 and CD16, to maximize NK cell activation through its proprietary Cross-Over-Dual-Variable-Domain (CODV) format. It is revolutionizing patient treatments in the fight against BCMA.
The dose escalation and dose expansion study of SAR’514 in monotherapy offers an exciting opportunity to evaluate the safety, pharmacokinetics and preliminary efficacy of the therapy in patients with RRMM and RRLCA. This study will provide invaluable insight into the potential of this novel therapy to help those living with these conditions.
We are delighted to announce the success of SAR’514/IPH6401, the second molecule from our ANKET® platform, in reaching the clinical stage. This advanced therapy has the potential to be a groundbreaking solution for patients suffering from Relapsed/Refractory Multiple Myeloma or Light-chain Amyloidosis, as it applies the groundbreaking concept of bringing together two activating receptors – NKp46 and CD16 – to activate NK cell effector functions against cancer cells. Joyson Karakunnel, MD, MSc, FACP, Chief Medical Officer at Innate Pharma, attests to the power of this promising new innovation.
We are thrilled to announce the first patient dosed with SAR’514 / IPH6401 as a result of our continued collaboration with Innate Pharma. This development represents a major step forward in harnessing the power of NK cells to fight cancer.
We are eager to leverage the potential of this novel therapy to lead to better patient outcomes for those suffering from relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA). We are confident that this cutting-edge research will improve the lives of many individuals.
The start of the trial marks a significant milestone for Innate, as Sanofi make their first payment as part of the research collaboration between the companies. This milestone payment is a strong testament to the progress that has been achieved since the collaboration began.
Innate is revolutionizing cancer treatment with their proprietary Antibody-based NK cell Engager Therapeutics (BLANKET®) platform. This cutting-edge technology is designed to create next-generation, multi-specific natural killer (NK) cell engagers to treat specific types of cancer and provide more effective treatments.
This groundbreaking technology is revolutionizing the fight against cancer by giving rise to a new class of molecules that can induce synthetic immunity. Spearheading the charge to a world free from this devastating disease, this fit-for-purpose innovation brings us one step closer to a cure.
About the Innate-Sanofi agreements:
Innate and Sanofi are joining forces to apply Innate’s cutting-edge technology in the development of advanced multi-specific antibodies with the power to activate NK cells via NKp46 and CD16 receptors for the purpose of eliminating tumor cells. This novel collaboration and license agreement is set to revolutionize cancer therapy.
About Innate Pharma
Innate Pharma S.A. is a biotechnology powerhouse transforming cancer treatment through groundbreaking immunotherapies. By leveraging its revolutionary ANKET® (Antibody-based NK Cell Engager Therapeutics) platform, Innate Pharma is helping to activate the innate immune system and revolutionize patient care. With clinical trials underway, Innate Pharma is paving the way for innovative treatments for cancer patients on a global scale.
Innate Pharma’s line of treatments boast promising potential to revolutionize cancer therapy. Lead product lacutamab is designed to target advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas, while monalizumab, co-developed with AstraZeneca, is a promising treatment for non-small cell lung cancer. Moreover, ANKET® multi-specific NK cell engagers offer exciting possibilities for tackling a variety of tumor types.
Innate Pharma is an invaluable partner for biopharmaceutical giants like Sanofi and AstraZeneca as well as eminent research institutions, dedicated to expediting medical advances and boosting progress for the betterment of all patients.
Headquartered on two sides of the Atlantic, Innate Pharma is a global biotechnology company with offices in Marseille, France and Rockville, MD, USA. Founded in 1999, Innate Pharma is listed on both Euronext Paris and Nasdaq, working to develop life-changing medicines that address unmet medical needs.